{
    "2020-09-09": [
        [
            {
                "time": "",
                "original_text": "医药生物行业9月投资策略：基本面无虞，Q4有望反转",
                "features": {
                    "keywords": [
                        "医药生物",
                        "9月",
                        "投资策略",
                        "基本面",
                        "Q4",
                        "反转"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[路演]乐普医疗：未来3-5年海外市场收入占比持续提升到20%-30%",
                "features": {
                    "keywords": [
                        "乐普医疗",
                        "路演",
                        "海外市场",
                        "收入占比",
                        "3-5年",
                        "20%-30%"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}